A Phase III, Open-Label Study of Maintenance LURBINECTEDIN in Combination With ATEZOLIZUMAB Compared With ATEZOLIZUMAB in Participants With Extensive-Stage Small Cell Lung Cancer .
PHARMAMAR HA OPTADO POR LA RETIRADA DE LA SOLICITUD DE AUTORIZACIÓN DE COMERCIALIZACIÓN DE APLIDIN ( PLITIDEPSIN ) ... WITHDRAWAL OF APPLICATIÓN FOR THE MARKETING AUTHORISATION OF APLIDIN ( PLITIDEPSIN ) JULY 23 , 2025 .
A Phase III, Open-Label Study of Maintenance LURBINECTEDIN in Combination With ATEZOLIZUMAB Compared With ATEZOLIZUMAB in Participants With Extensive-Stage Small Cell Lung Cancer .